OverviewChartTechnicalNewsTraderScreen

Minerva Neurosciences Inc/  US6033802058  /

NASDAQ
2024-04-26  3:40:38 PM Chg. +0.0600 Volume Bid3:41:31 PM Ask3:41:31 PM High Low
2.4900USD +2.47% 1,128
Turnover: 2,644.8200		 2.4300Bid Size: 4,400 2.4800Ask Size: 100 2.4900 2.4300
GlobeNewswire 02-27 Minerva Neurosciences Receives Complete Response Letter from FDA for New Drug Application for Rolupe...
GlobeNewswire 02-22 Minerva Neurosciences Reports Fourth Quarter and Fiscal Year 2023 Financial Results and Business Upd...
GlobeNewswire 2023-11-07 Minerva Neurosciences Reports 2023 Third Quarter Financial Results and Business Updates
GlobeNewswire 2022-03-01 Minerva Neurosciences Reports Fourth Quarter 2021 Financial Results and Business Updates
GlobeNewswire 2022-02-28 Minerva Neurosciences Announces Publication of Roluperidone Phase 3 Study Results in Schizophrenia B...
GlobeNewswire 2022-01-25 Immunovant Appoints Mark Levine as Chief Legal Officer
GlobeNewswire 2021-11-08 Minerva Neurosciences Reports Third Quarter 2021 Financial Results and Business Updates
GlobeNewswire 2021-11-03 Minerva Neurosciences Announces FDA Recommendation for Type C Meeting to Discuss Evidence for Use of...
GlobeNewswire 2021-11-01 Minerva Neurosciences to Report Third Quarter 2021 Financial Results and Business Updates on Novembe...
GlobeNewswire 2021-10-11 Minerva Neurosciences Announces Promotion of Geoff Race to President
GlobeNewswire 2021-09-30 Minerva Neurosciences Announces Study Results Demonstrating Bioequivalence of Phase 2b, Phase 3, and...
GlobeNewswire 2021-09-08 Minerva Neurosciences Announces Appointment of Dr. Ramana Kuchibhatla as Senior Vice President and...
GlobeNewswire 2021-07-26 Minerva Neurosciences to Report Second Quarter 2021 Financial Results and Business Updates on August...
GlobeNewswire 2021-06-14 Yumanity Therapeutics Appoints Devin W. Smith as General Counsel
GlobeNewswire 2021-06-10 Minerva Neurosciences to Present at JMP Securities Life Sciences Conference
GlobeNewswire 2021-05-28 Minerva Neurosciences to Present at Jefferies Virtual Healthcare Conference
GlobeNewswire 2021-05-12 Minerva Neurosciences Reports First Quarter 2021 Financial Results and Business Updates
GlobeNewswire 2021-05-11 Minerva Neurosciences Announces the Results of the Phase 3 Trial of Roluperidone for the Treatment o...
GlobeNewswire 2021-05-05 Minerva Neurosciences to Report First Quarter 2021 Financial Results and Business Updates on May 12,...
GlobeNewswire 2021-03-18 Talis Appoints Jeryl Hilleman to Board of Directors
GlobeNewswire 2021-03-08 Minerva Neurosciences Reports Fiscal 2020 Fourth Quarter and Year End Financial Results and Business...
GlobeNewswire 2021-03-01 Minerva Neurosciences to Report Fiscal 2020 Fourth Quarter and Year End Financial Results and Busine...
GlobeNewswire 2021-02-06 MINERVA FINAL DEADLINE NOTICE: ROSEN, TOP RANKED INVESTOR COUNSEL, Encourages Minerva Neurosciences,...
GlobeNewswire 2021-02-05 IMMINENT SHAREHOLDER DEADLINE: Block & Leviton LLP Reminds Shareholders that it Has Filed a Lawsuit ...
GlobeNewswire 2021-02-04 Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Min...